By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The University of Washington and Pharmigene today announce the resolution of a patent dispute and the subsequent licensing of technology to Pharmigene for determining proper dosing for the anti-coagulant drug warfarin.

The agreement settles a patent interference "concerning previously competing applications that describe methods to determine proper dosing of … warfarin," the two firms said in a joint statement. No additional details were provided.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.